Author: Admin

Developer

Release – ProMIS Neurosciences Announces Special Shareholder Meeting

Posted on by Admin


ProMIS Neurosciences Announces Special Shareholder Meeting

 

TORONTO, Ontario and CAMBRIDGE, Mass. – October 7, 2021 – ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that it will hold a special general meeting of shareholders (the “Special Meeting”) on December 1, 2021. The Company has set October 18, 2021, as the record date for the Special Meeting.

The purpose of the Special Meeting is to ask shareholders to grant the Board of Directors (the “Board”) the authority, exercisable in the Board’s discretion, to consolidate (or reverse split) the Company’s issued and outstanding common shares in furtherance of a potential listing of the Company’s shares on a stock exchange in the United States.  The full particulars of the special business will be set out in the management information circular for the Special Meeting, which will be mailed to shareholders and filed on SEDAR after the record date. 

“With the recent closing of our successful financing, our lead program PMN310 is presently on track to complete all of the work necessary to file an IND in the second half of 2022 as well as initiate Phase 1 clinical trials soon thereafter,” stated Eugene Williams, the Company’s Executive Chairman.   “We believe a listing on a stock exchange in the United States, which should provide greater liquidity for our shareholders, should also provide greater access to capital to help expedite the development of our potential therapies and the process of obtaining clinical validation of such potential therapies.”

At the Special Meeting, the shareholders will be specifically asked to consider, and if deemed advisable, pass a special resolution authorizing the Board to determine, at its discretion, to file articles of amendment to consolidate the common shares of the Company at a consolidation ratio within the range to be specified in the proxy materials.  Subject to shareholder approval, the Board intends to proceed with a share consolidation in furtherance of a listing of the Company’s shares on a stock exchange in the United States but there can be no assurances that any such listing will occur following shareholder approval, a share consolidation or otherwise.  Further, there is no assurance that the Company will meet the quantitative or qualitative requirements to list on a stock exchange in the United States.  Finally, notwithstanding approval of the resolution by shareholders, the Board will retain the discretion to elect not to proceed with the share consolidation.

Any authority proposed to be granted to the Board to consolidate the shares is conditional upon the prior approval of the Toronto Stock Exchange.

About ProMIS Neurosciences 

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMI and Collective Coordinates—to predict novel targets, known as Disease Specific Epitopes, on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

For further information about ProMIS Neurosciences, please consult the Company’s website at: www.promisneurosciences.com  

For Investor Relations please contact: 

Alpine Equity Advisors Nicholas Rigopulos, President nick@alpineequityadv.com Tel. 617 901-0785 

 

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.  

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur including, but not limited to, statements related to the intent of the Company to pursue a potential listing of its common shares on a stock exchange in the United States and the potential benefits to the Company and its shareholders related to such a listing, the Company conducting a share consolidation in furtherance of a potential listing of its common shares on a stock exchange in the United States and the potential timing for the filing of an IND and the commencement of clinical trials related to the Company’s lead program PMN310. Readers are cautioned that forward-looking statements are based on certain assumptions and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by such forward-looking information will not occur.  Such risks and uncertainties with respect to the forward-looking statements contained in this news release include, but are not limited to, the Company obtaining shareholder and Toronto Stock Exchange approval for a consolidation of its common shares, the Company’s ability to generally meet the quantitative and qualitative requirements to list its common shares on a stock exchange in the United States, the trading volumes in the Company’s common shares increasing as a result of a listing on a stock exchange in the United States, the Company’s ability to access capital improving as a result of a listing on a stock exchange in the United States, and the Company obtaining the necessary regulatory approvals and satisfying the other requirements to file an IND and commence its clinical trials related to its lead program PMN310 soon thereafter.  Readers should also refer to the risk factors set forth in the Company’s continuous disclosure documents available at SEDAR (www.sedar.com). There can be no assurance that the plans, intentions or expectations upon which forward-looking statements are based will be realized. Actual results may differ, and the difference may be material and adverse to the Company and its shareholders.  Therefore, readers should not place undue reliance upon such forward-looking statements.  The Company does not intend, and does not assume any obligation, to update these forward-looking statements in order to reflect events or circumstances that may arise after the date of this news release except as required by applicable law or regulatory requirements. 

Release -Sierra Metals Completes Strategic Review Process Initiates Annual Base Dividend of US$0.03 Per Share and Appoints Two New Directors to Its Board

Posted on by Admin


Sierra Metals Completes Strategic Review Process, Initiates Annual Base Dividend of US$0.03 Per Share and Appoints Two New Directors to Its Board

 

TORONTO–(BUSINESS WIRE)– Sierra Metals Inc. (TSX: SMT) (BVL: SMT) (NYSE AMERICAN: SMTS) (“Sierra Metals” or “the Company”) announces today that its Board of Directors (the “Board”) has completed its previously announced review of strategic alternatives.

Based on an extensive review of various alternatives, the Board has determined, in consultation with its financial and legal advisors, that maximum value for shareholders will be delivered through the pursuit by the Company of various strategic value-enhancing opportunities.

Within its current assets and diversified extensive resource base, the Company will continue to focus its efforts on growing the production of the metals expected to feed into the anticipated global infrastructure supply demands. The increased focus will apply specifically to copper and steel-making products (zinc and iron ore), with the production of the precious metals as a valuable cost-credit byproduct.

Furthermore, the Company has completed an actionable review of its assets and will consider appropriate further action over the Company’s portfolio of assets. This action could take the form of divestments, joint ventures (“JVs”) or partnerships, and it could include assets such as the Cusi Silver Mine or exploration targets which lie outside the current operating areas.

Sierra Metals believes in the importance of Environmental, Social and Corporate Governance and will proceed with a heightened focus on these matters with a view to maintaining the best applicable practices in each of these areas. We strive for excellence in fulfilling our environmental and social duties and responsibilities, ultimately sharing increased wellbeing with our workforce and in the communities where we operate.

The Company will continue with a disciplined capital allocation approach and the use of funds on sustaining and growth projects, using a stringent stage-gate process with a close follow-up on implementation and delivery of projects which include:

  • Delivery of current Prefeasibility Studies for mine expansion at our 3 operations, starting with Bolivar Mine, followed by Yauricocha and Cusi.
  • Advancing with the inclusion into the Company’s mine plans of certain near-term underground and brownfield mine opportunities with the aim of increasing the return at the Yauricocha and Bolivar Mines.

Following COVID restrictions that limit the Company on its exploration activities, greenfield exploration on our extensive 110,000-hectare land packages will be reactivated in due course to develop new and expanded mineral resource opportunities. The Company will be open to JVs and partnerships for these opportunities.

Jose Vizquerra-Benavides, Chairman of the Board of Sierra Metals, said, “We have reached the end of the strategic review process announced early this year. This process, which has taken longer than usual due to COVID, has been instrumental in highlighting the value of our current operations and the value-enhancing opportunities that are available for development. The process has allowed us to develop a strategy that will guide our efforts for the coming years, including a renewed focus on green and steel-related metals, the inclusion of added value from our current extensive land holdings and shared wellbeing with our stakeholders.”

Luis Marchese, CEO of Sierra Metals, said: “The Company expects to have more robust EBITDA and free cash flow starting next year and carrying on into the coming years. This is a benefit of the recent throughput expansions, which are expected to increase production across our suite of metals, hand in hand with strengthened metal prices based on current consensus metal price projections. Our newly instituted dividend policy has been inaugurated on the back of these positive developments and speaks to our belief in Company and our ability to deliver on our growth initiatives. Over the past several years, we have made significant changes across the organization, streamlining our business, strengthening our team, optimizing our operations, and driving much-improved financial performance. Our operations have not only proven themselves to be quite resilient in these uncertain times, but we also expect to emerge from the pandemic and the strategic review process as a significantly stronger Company with a strong focus on growth and value creation for all shareholders as we execute our strategy.”

Annual Dividend

In addition, the Board has authorized the payment of an annual dividend to consist of a base dividend of US$5 million or US$0.03 per share plus an additional amount based on available cash flows generated each year after accounting for planned capital spending, distributions to non-controlling interests, greenfield exploration and mandatory debt service. The initial dividend is expected to be declared in November 2021 and paid to shareholders in December 2021. Additional details of this dividend will be provided in a subsequent press release.

Appointment of New Directors

The Board is also pleased to announce the appointment of Carlos E. Santa Cruz and Oscar M. Cabrera to the Board, effective immediately. Messrs. Cabrera and Santa Cruz have been appointed following the resignation of two directors earlier this year.

Mr. Santa Cruz is a Mining Engineer with over 40 years of experience of strong international managerial background in mining operations at a senior level. He held positions with major mining companies, including Senior Vice-President of Australian and New Zealand Operations and Senior Vice-President of South American Operations for Newmont. He currently sits as Chairman of the Board for BISA Ingenieria de Proyectos S.A.. and Director for JRC Ingeniería y Construcción S.A.C. Mr. Santa Cruz is an Independent Mining Consultant and Part-time Professor at Pontificia Universidad Católica and is a member of Industry Advisory Committees at Penn State and Piura University. Chairman of the Board for CIMADE, NGO oriented to promote sustainable mining and infrastructure megaprojects. Mr. Santa Cruz holds a Ph.D., Mining Engineering and M Eng., Industrial Engineering from Penn State University, as well as the Advanced Management Program from Harvard University. Mr. Santa Cruz is a Peruvian Citizen.

Mr. Cabrera is a Senior equity analyst with over 20 years of experience covering the metals and mining industry for bulge bracket investment banks and Canadian financial institutions, including Goldman Sachs, Merrill Lynch Canada and CIBC World Markets. He obtained recognition for industry thought leadership, fundamental commodity analysis and strong industry relationships, which has led to advisory roles for public mining companies, including Nexa Resources S.A. He also participated in the vetting of and advising on primary and secondary offerings in Canada, the U.S. and Europe. Mr. Cabrera holds a MBA from York University, a M Eng. in Structural Engineering from the University of Toronto and a B. Sc in Civil Engineering from the Instituto Tecnológico y de Estudios Superiores de Monterrey. Mr. Cabrera is a Canadian Citizen, originally from Mexico.

Jose Vizquerra-Benavides commented, “We are extremely pleased to have Carlos and Oscar join the Board of Sierra. Their extensive knowledge of mining operations and projects both in Peru and Mexico as well as commodity analysis and capital markets will benefit the Company as we progress on a plan of growth and value creation for all stakeholders.”

About Sierra Metals

Sierra Metals Inc. is a diversified Canadian mining company focused on the production and development of precious and base metals from its polymetallic Yauricocha Mine in Peru, and Bolivar and Cusi Mines in Mexico. The Company is focused on increasing production volume and growing mineral resources. Sierra Metals has recently had several new key discoveries and still has many more exciting brownfield exploration opportunities at all three Mines in Peru and Mexico that are within close proximity to the existing mines. Additionally, the Company also has large land packages at all three mines with several prospective regional targets providing longer-term exploration upside and mineral resource growth potential.

The Company’s Common Shares trade on the Bolsa de Valores de Lima and on the Toronto Stock Exchange under the symbol “SMT” and on the NYSE American Exchange under the symbol “SMTS”.

For further information regarding Sierra Metals, please visit www.sierrametals.com.

Continue to Follow, Like and Watch our progress:

Web: www.sierrametals.com | Twitter: sierrametals | Facebook: SierraMetalsInc | LinkedIn: Sierra Metals Inc

Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of Canadian and U.S. securities laws (collectively, “forward-looking information“). Forward-looking information includes, but is not limited to, statements with respect to the date of the 2020 Shareholders’ Meeting and the anticipated filing of the Compensation Disclosure. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”, “plans”, “projects”, “estimates”, “assumes”, “intends”, “strategy”, “goals”, “objectives”, “potential” or variations thereof, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking information.

Forward-looking information is subject to a variety of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, the risks described under the heading “Risk Factors” in the Company’s annual information form dated March 30, 2020 for its fiscal year ended December 31, 2019 and other risks identified in the Company’s filings with Canadian securities regulators and the United States Securities and Exchange Commission, which filings are available at www.sedar.com and www.sec.gov, respectively.

The risk factors referred to above are not an exhaustive list of the factors that may affect any of the Company’s forward-looking information. Forward-looking information includes statements about the future and is inherently uncertain, and the Company’s actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors. The Company’s statements containing forward-looking information are based on the beliefs, expectations and opinions of management on the date the statements are made, and the Company does not assume any obligation to update such forward-looking information if circumstances or management’s beliefs, expectations or opinions should change, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.

Mike McAllister, CPIR
Vice President, Investor Relations
Sierra Metals Inc.
Tel: +1 (416) 366-7777
Email: info@sierrametals.com

Luis Marchese
CEO
Sierra Metals Inc.
Tel: +1 (416) 366-7777

Source: Sierra Metals Inc.

MedX Health (MDXHF)(MDX.V) – New Developments in Pain Management – a NobleCon Online Investor Event

Posted on by Admin

MedX Health President of Dermatology Services Mike Druhan delivers a formal corporate overview, followed by a Q & A session moderated by Noble Capital Markets Senior Healthcare Services & Medical Devices Analyst Gregory Aurand.

Return to the Investor Forum Event Page

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.

News & Advanced Market Data on MDXHF

Release – Gevo Partners with Engineering Procurement and Construction (EPC) Giant Kiewit on its Net-Zero 1 Project

Posted on by Admin


Gevo Partners with Engineering, Procurement, and Construction (EPC) Giant, Kiewit, on its Net-Zero 1 Project

 

ENGLEWOOD, Colo., Oct. 07, 2021 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) is pleased to announce it has engaged Kiewit Energy Group Inc. to lead the Front End Engineering Design (FEED) effort for its Net-Zero 1 Project in Lake Preston, South Dakota. Kiewit Energy Group Inc. is part of Kiewit Corporation, one of the top five contractors in the U.S. with vast experience in virtually every energy segment. This includes extensive work on energy-transition projects such as biofuel plants, geothermal plants, solar farms, and building the first offshore wind substation project in the U.S., as well as a wide range of projects for large oil-and-gas companies. Gevo expects Kiewit Energy Group Inc. will fulfill the engineering, procurement, and construction (EPC) role in the project once the FEED phase is complete.

“Kiewit’s comprehensive construction and engineering capabilities match its tremendous project experience in the energy sector, specifically the clean energy sector,” said Dr. Chris Ryan, President and Chief Operating Officer of Gevo, Inc. “Working with a firm like this, we expect to reduce execution risk on the Net-Zero 1 Project while increasing our capability to build out multiple net zero plants as the market demands—good news for our growing list of customers, shareholders, and folks who care about the environment.”

Kiewit is considered one of the leading construction and engineering firms in North America. Founded in 1884, the company has grown to more than 27,000 dedicated staff and skill craft workers. Active in markets across the industrial, mining, energy, building and transportation sectors, Kiewit had revenues of $12.5 billion in 2020 and has extensive experience delivering small-scale projects up to multi-billion-dollar programs.

”We’re very pleased that Gevo selected us to bring our design, engineering and construction expertise to support this innovative, important clean energy project,” said Ben Bentley, executive vice president, Kiewit Energy Group Inc. “We’ve seen firsthand Gevo’s strategic plans and commitment to help bring this and other net zero plants to market. We’re excited to deliver on this contract and expand our partnership in the coming years with a leader in this growing sector.”

Kiewit is a leader in safety and quality and committed to environmental stewardship. Kiewit is led by experienced managers at all levels, and its LEED®-accredited professionals are trained to achieve green objectives and support green designs. The firm has delivered more than 500 energy transition projects in virtually every energy market segment ranging from renewable and alternative fuels to energy storage and carbon capture, to chemical recycling and renewable power. With deep expertise in, and an understanding of, the technology necessary to build first-of-its-kind facilities, Kiewit is known for its leadership and ability to deliver complex projects. The company also has one of the largest and most modern, privately owned equipment fleets in North America.

“Kiewit’s ability to self-perform set them apart for us,” Dr. Ryan says. “And because the firm is large enough to take on multiple large projects, it will be capable of meeting our needs as we enter the expected next phase of our business.”

About Gevo

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full life cycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their life cycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low-carbon products such as gasoline components, jet fuel and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Gevo believes that the Argonne National Laboratory GREET model is the best available standard of scientific-based measurement for life cycle inventory or LCI.

Learn more at Gevo’s website: www.gevo.com

About Kiewit

Kiewit is one of North America’s largest and most respected construction and engineering organizations. With its roots dating back to 1884, the employee-owned organization operates through a network of subsidiaries in the United States, Canada, and Mexico. Kiewit offers construction and engineering services in a variety of markets including transportation; oil, gas and chemical; power; building; water/wastewater; industrial; and mining. Kiewit had 2020 revenues of $12.5 billion and employs 27,000 staff and craft employees.

Learn more at Kiewit’s website: www.kiewit.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, without limitation, including Kiewit engineering and construction for Net-Zero 1 FEED phase and beyond, the production of SAF, the attributes of Gevo’s products, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

Investor and Media Contact

+1 720-647-9605

IR@gevo.com

Release – Capstone Green Energy Awarded Two Megawatt CCHP Order for Multi-State Industrial Grow Operator and Secures 20 Year Service Plan

Posted on by Admin

 


Capstone Green Energy (NASDAQ:CGRN) Awarded Two Megawatt CCHP Order for Multi-State Industrial Grow Operator and Secures 20 Year Service Plan

 

The 2 Megawatt CCHP System Will Work in Parallel With the Local Utility and Produce 880 Nominal Tons of Cooling Capacity To Be Distributed Throughout Operator’s Maryland Facility

VAN NUYS, CA / ACCESSWIRE / October 7, 2021 / Capstone Green Energy Corporation (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN), a global leader in carbon reduction and on-site resilient green energy solutions, announced today it has secured a contract for two C1000S microturbines for a state-of-the-art energy system for an industrial grow operator’s Maryland cultivation and processing facility.

The order, secured by E-Finity Distributed Generation (www.e-finity.com), Capstone’s exclusive distributor for the Mid-Atlantic, Southeastern United States, and the Caribbean, is expected to be commissioned in the summer of 2022.

Two Capstone natural gas-fueled C1000 Signature Series microturbine energy systems will use their waste heat for two exhaust-fired absorption chillers that will produce 880 tons of chilled water to be used for space conditioning of the 90,000 square foot facility. The resilient system will be capable of islanding from the electric utility in the case of a power outage and should provide continuous operation to the grow facility.

“The combined heat and power (CHP) plant is designed to meet the facility’s strict cooling demand while protecting the customer from the high operational costs of operating a chilled water plant,” said Tom McGeehan, E-Finity’s Vice President of Sales.

The system is expected to save the customer millions of dollars over the life of the product and to reduce emissions by over 13 million pounds of CO2 per year, which is equivalent to removing over 1,110 cars from the road.

“We continue to see an increase in project opportunities in the global industrial grow house and greenhouse industry as they are realizing maximum benefits from on-site green energy, including cost savings and increased resiliency,” said Darren Jamison, Capstone Green Energy President and Chief Executive Officer. “While both of these are critical for efficient operations, our green energy systems also offer significant environmental benefits,” concluded Mr. Jamison.

About Capstone Green Energy
Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Conversion Products are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Products business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen Energy Solutions, Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: rentals@CGRNenergy.com. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three years are estimated at 1,115,100 tons of carbon and $698 million in annual energy savings.

For more information about the Company, please visit: www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on Twitter, LinkedIn, Instagram, Facebook, and YouTube.

Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations for green initiatives and execution on the Company’s growth strategy and other statements regarding the Company’s expectations, beliefs, plans, intentions, and strategies. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT:
Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
ir@CGRNenergy.com

SOURCE: Capstone Green Energy Corporation

Newrange Gold Corp. (NRGOF)(NRG:CA) – The Opportunity Set at Pamlico Could Expand Beyond Gold

Posted on by Admin

Thursday, October 07, 2021

Newrange Gold Corp. (NRGOF)(NRG:CA)
The Opportunity Set at Pamlico Could Expand Beyond Gold

As of April 24, 2020, Noble Capital Markets research on Newrange Gold is published under ticker symbols (NRGOF and NRG:CA). The price target is in USD and based on ticker symbol NRGOF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Newrange Gold Corp is an exploration stage company focused on acquiring and exploring exploration and evaluation assets in Colombia and the United States. The Company operates in a single reportable operating segment-the acquisition, exploration, and development of mineral properties. Some of the projects acquired by the company are Pamlico gold project in Nevada and Rocky mountain project in Colorado. The company also holds an interest in the Yarumalito property, El Dovio property and Anori property in Colombia.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Assay results yield a few surprises. Assay results were released for four follow-up diamond core holes representing 800.6 meters of drilling around Hole P21-115, a reverse circulation hole that discovered shallow, high-grade oxide gold mineralization just east of the Merritt Zone and north of the historic Pamlico mine. Instead of gold mineralization resembling that observed in Hole P21-115, Holes P21-122 through P21-125 revealed concentric halos of zinc, lead, copper, arsenic, silver, and higher gold values near the center.

    Looking through a broader lens.  Information from geophysical work, mapping, and rock and soil sampling point to strong intrusive activity in the southern part of the property, with widespread copper, zinc, silver, and gold mineralization. Coupled with recent diamond drilling, the company appears to be outlining a large-scale polymetallic system …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Great Lakes Dredge & Dock (GLDD) – Smooth CFO Transition Underway and Another Low Bid Out

Posted on by Admin

Thursday, October 07, 2021

Great Lakes Dredge & Dock (GLDD)
Smooth CFO Transition Underway and Another Low Bid Out

Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The company only’s operating segments is Dredging. Dredging involves the enhancement or preservation of navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand or rock. Its projects portfolio includes Coastal Restoration, Coastal Protection, Port expansion, and others.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Smooth CFO transition underway. We caught up yesterday with Scott Kornblau who recently joined as SVP and CFO. Based on our meeting, we believe that Scott is a great addition to the executive team, and his 20-plus years of experience, including CFO at Diamond Offshore Drilling, has made the transition smooth. The change was driven by the HQ relocation, and Scott is already up and running in Houston. We expect no changes to the current strategic direction, including moving into offshore wind. We will miss the former CFO, but look forward to working with Scott.

    Another low bid out.  Bids on South Atlantic Regional Harbor Dredging (W912PM21B0008) were opened on Tuesday afternoon and GLDD was the low bidder at $29.4 million. The IGE was $28.3 million and Manson bid $31.6 million. The work includes work at five harbors along the east coast and is broken down as follows: $8.3 million for Morehead City, $4.6 million for Wilmington, $4.5 million for Brunswick …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Avivagen Inc. (VIVXF)(VIV:CA) – Management Call on AB Vista Distribution Agreement

Posted on by Admin

Thursday, October 07, 2021

Avivagen Inc. (VIVXF)(VIV:CA)
Management Call on AB Vista Distribution Agreement

Avivagen Inc is a Canadian based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s own health defenses. Its product range includes OxC-beta, Vivamune health chews, Oximunol chewable tablets, and Carotenoid Oxidation products.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Agreement. As we had anticipated, Avivagen has entered into a distribution agreement focused on the U.S., Brazil, and Thailand markets. The 8-year agreement is with AB Vista. We expect the agreement to expand the adoption and use of OxC-beta in a number of high-value feed production markets worldwide. The AB Vista agreement should bring additional credibility for OxC-beta across the feed additive industry.

    Who Is AB Vista? AB Vista is a a global animal nutrition technology company supplying feed additives, nutrition expertise and analytical services to animal feed and protein producers.  The Company is one of the top distributors of feed enzymes worldwide, with a large technical sales force. We believe AB Vista will be able to leverage its existing relationships and distribution partnerships for …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Global Regulators Release Principles for Financial Market Infrastructures to Stablecoin

Posted on by Admin 


	Image Credit: Wes Levitt (Theta Labs)

Stablecoin’s Giant Leap Forward Toward Global Adoption

 

Formal guidance on stablecoin arrangements from two international financial authorities has just been released. The guidance is largely seen as positive news for the cryptocurrencies that peg their value to more traditional monetary benchmarks. In a 22-page report that is the result of the G7, G20 and the Financial Stability Board (FSB) request from the Bank for International Settlements (BIS) and the International Organization of Securities Commissions (IOSCO), uniform principles and priorities were outlined.

Overall, the report titled, “Application of the
Principles for Financial Market Infrastructures to Stablecoin Arrangements” favors rules that follow all relevant principles that guide other monetary systems.  It provides guidance on the topics of Governance, Risk Management, and Settlements.

Governance

In the category of governance, the authors of the guidance believe a stablecoin asset should consider the assets ownership structure and operation while allowing for clear and direct lines of responsibility and accountability. For example, it should be owned and operated by one or more identifiable and responsible legal entities that are ultimately controlled by individuals. The accountable individual(s) responsible for a stablecoins structure and operation will provide adherence to all rules of governance and other related functions.

 

Risk Management

A stablecoin asset operation should regularly review the material risks that the financial market infrastructure (FMI) could pose. It should oversee its function as well as critical entities such as, settlement banks, liquidity providers, transfer operations, and other service providers.  The stablecoin should develop appropriate risk-management frameworks and tools identify and address these risks. Of particular importance, it should identify and implement appropriate risk-reductions, from an integrated and comprehensive view of the entire stablecoin environment.

 

Settlement Finality

An active stablecoin should provide clear and final settlement, regardless of the settlement method used. The stablecoin should clearly define the point at which a transfer on the ledger becomes irrevocable and technical settlement happens and make it transparent whether and to what extent there could be a misalignment between technical settlement and legal finality.  The stablecoin should also ensure proper transparency regarding mechanisms for reconciling any misalignment between technical settlement and legal finality. Standard measures should be in place to resolve the potential losses that could be created in case of reversals stemming from misalignment between technical settlement and legal finality.

 

Money Settlements

Money settlements should have little or no credit or liquidity risk. In assessing the risk presented by the stablecoin, the operator should consider whether the coin provides its holders with a direct legal claim on the issuer and/or claim on, title to or interest in the underlying reserve asset for timely convertibility at par into other liquid assets. It should have a clear process for fulfilling holders’ claims in both normal environments and those that are more stressed.

Credit and liquidity risks of the stablecoin should be controlled so its uses for money settlements are minimized and controlled so that stablecoin is an acceptable alternative to the use of central bank money.

 

Take-Away

The payments landscape is undergoing rapid transformation. While there is no roadmap for any new payment method, international overseers and regulators are trying to devise a workable and uniform framework so developers and operators can devise their currencies to adhere to certain principles and standards.

The consultative report, requested by powerful world groups, will allow stablecoin assets providers to have a basis for design that will assure uniformity and potentially greater acceptance.

 

Do You Know a Student Interested in This Year’s College
Challenge?

 

Suggested Reading:



SPAC Places “Hard Circle” Around Stablecoin Company

Crypto’s Ancillary Businesses as an Opportunity for Investors

 

Sources:

https://www.thetatoken.org/

https://www.iosco.org/library/pubdocs/pdf/IOSCOPD685.pdf

https://www.reuters.com/article/crypto-currency-stablecoins-regulator/stablecoins-to-face-same-safeguards-as-traditional-payments-idUSL8N2R11HX

https://www.barrons.com/articles/stablecoins-just-got-a-step-closer-to-global-regulation-51633522382?mod=hp_INTERESTS_economy-and-policy&refsec=hp_INTERESTS_economy-and-policy

Release – PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer

Posted on by Admin


PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer

 

FLORHAM PARK, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Matthew Hill will join PDS Biotech as its Chief Financial Officer (CFO) effective as of October 18, 2021, to lead the company’s financial strategy through its next phase of growth.

Mr. Hill brings more than 25 years of experience in finance and operational leadership roles for life science companies. He is joining PDS Biotech after spending the last several years at Strata Skin Sciences (Nasdaq: SSKN) as their Chief Financial Officer, where he led the financial vision and strategy for the medical device company. Prior to joining Strata Skin Sciences, he held CFO roles at several companies, including Velcera prior to its acquisition by the Perrigo Company, and EP Medsystems prior to its acquisition by St. Jude Medical, where he also served as the VP of Operations. Mr. Hill holds a Bachelor of Science in accounting from Lehigh University.  

“Given the promise of the Versamune® platform in oncology, I’m excited to bring my experience with life science companies to PDS Biotech’s next chapter. PDS has achieved significant milestones in the last year and I am energized to contribute my expertise and leadership to direct PDS Biotech’s financial strategy to facilitate its next phase of growth,” said Hill.

“We are focused on developing and commercializing novel and more effective treatments for cancer,” said PDS Biotech President and CEO Dr. Frank Bedu-Addo. “Matt’s extensive experience with growth-stage healthcare and life science companies will provide PDS Biotech with solid financial leadership and I look forward to working closely with Matt to fulfill the promise demonstrated thus far of bringing novel oncology products to the market.”

Mr. Hill will replace Seth Van Voorhees in the role of CFO.   Dr. Bedu-Addo continued, “On behalf of our board of directors, we would like to thank Seth for his service to the company and wish him continued success in his future endeavors.”

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The company’s pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers.   To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company’s or monitoring committees’ or other third parties’ interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment, significance of milestones, and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: rich@cg.capital

Release – ACCO Brands Corporation Announces Third Quarter 2021 Earnings Webcast

Posted on by Admin


ACCO Brands Corporation Announces Third Quarter 2021 Earnings Webcast

 

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that it will release its third quarter 2021 earnings after the market close on October 26, 2021. The Company will host a conference call and webcast to discuss the results on October 27 at 8:30 a.m. EDT. The webcast can be accessed through the Investor Relations section of www.accobrands.com and will be available for replay.

About ACCO Brands Corporation

ACCO Brands Corporation (NYSE: ACCO) is one of the world’s largest designers, marketers and manufacturers of branded academic, consumer and business products. Our widely recognized brands include Artline®, AT-A-GLANCE®, Barrilito®, Derwent®, Esselte®, Five Star®, Foroni®, GBC®, Hilroy®, Kensington®, Leitz®, Mead®, PowerA®, Quartet®, Rapid®, Rexel®, Swingline®, Tilibra®, Wilson Jones® and many others. Our products are sold in more than 100 countries around the world. More information about ACCO Brands, the Home of Great Brands Built by Great People, can be found at www.accobrands.com.

Christine Hanneman
Investor Relations
(847) 796-4320

Julie McEwan
Media Relations
(937) 974-8162

Source: ACCO Brands Corporation

Release – Voyager Digital Business Update for the Quarter Ended September 30, 2021

Posted on by Admin

 


Voyager Digital Business Update for the Quarter Ended September 30, 2021

 

NEW YORK, Oct. 6, 2021 /CNW/ – Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG) (OTCQX: VYGVF) (FRA: UCD2) one of the fastest-growing, publicly traded cryptocurrency platforms in the United States, today announced preliminary revenue and user metrics for the fiscal 2022 first quarter ended September 30, 2021.

“As we exit September and reflect on the growth of our platform, we are glad to report that our Company is stronger than ever,” said Stephen Ehrlich, CEO and Co-founder of Voyager. “Our marketing efforts are contributing to consistent user growth, and we’ve seen trading volume rebound following the general industry-wide downtrend witnessed in July. With international expansion and new products on the horizon, we’re more excited than ever about Voyager’s future and are positioned to operate within applicable regulatory frameworks.”

“As we continue to grow our funded accounts, Voyager’s transactional volume is contingent on market volume and the overall market volume decreased substantially in July and August. We have begun to diversify our revenue model to generate long term staking rewards providing recurring revenue. As we continue to develop staking capabilities, we expect that reward and yield revenue will generate a minimum of $40 – $50 million of rewards and yield revenue for the December quarter in addition to the standard transactional revenue,” added Mr. Ehrlich.

The Company is pleased to announce the following fiscal 2022 first quarter ended September 30, 2021 Financial and Operational Key Metrics:

  • Total funded accounts exceed 860,000, up 29% from 665,000 at fiscal year ended June 30, 2021
  • Total verified users on the platform now stand at more than 2.15 million, up 23% from 1.75 million at fiscal year ended June 30, 2021
  • Preliminary revenue for the quarter is estimated at $63 – 67 million, compared to $109 million for the fiscal fourth quarter ended June 30, 3021
  • Net new deposits were approximately $827 million, compared to the $1,620 million for the fiscal fourth quarter ended June 30, 2021

Sept 30, 2021

June 30, 2021

Sept 30, 2020

Revenues (millions)

$63 to $67 (1)

$109 (2)

$2

Total Funded Accounts

860,000

665,000

23,400

Total Verified Users

2,150,000

1,750,000

87,500

Net New Deposits (millions)

$827

$1,620

$36



(1)

preliminary and unaudited and subject to final adjustment.

(2)

unaudited

All amounts are in U.S. dollars, unless otherwise indicated.

About Voyager Digital Ltd.
Voyager Digital Ltd. (TSX: VOYG; OTCQX: VYGVF; FRA: UCD2) is a fast-growing, publicly traded cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 60 different crypto assets using its easy-to-use mobile application, and earn rewards up to 12 percent annually on more than 30 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.

The TSX has not approved or disapproved of the information contained herein.

Financial Disclaimer:
The preliminary estimated financial results and other data for the three months ended September 30, 2021 set forth above are subject to the completion of the Company’s financial closing procedures. This data has been prepared by, and is the responsibility of, the Company’s management and audit committee. Voyager’s independent registered public accounting firm, Marcum LLP, does not express an opinion or any other form of assurance with respect thereto. The Company currently expects that its final results of operations and other data for the interim period ended September 30, 2021 will be consistent with the estimates set forth above, but such estimates are preliminary and Voyager’s actual results of operations and other data could differ materially from these estimates due to the completion of its quarterly review procedures, final adjustments, and other developments that may arise between now and the time such unaudited consolidated financial statements for the three months ended September 30, 2021 are released.

Forward Looking Statements
Certain information in this press release, including, but not limited to, statements regarding future growth and performance of the business, momentum in the businesses, future adoption of digital assets, and the Company’s anticipated results may constitute forward looking information (collectively, forward-looking statements), which can be identified by the use of terms such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” (or the negatives) or other similar variations. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Voyager’s actual results, performance or achievements to be materially different from any of its future results, performance or achievements expressed or implied by forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward looking statements are subject to the risk that the global economy, industry, or the Company’s businesses and investments do not perform as anticipated, that revenue or expenses estimates may not be met or may be materially less or more than those anticipated, that trading momentum does not continue or the demand for trading solutions declines, customer acquisition does not increase as planned, product and international expansion do not occur as planned, risks of compliance with laws and regulations that currently apply or become applicable to the business or the interpretation or application of laws and regulations by regulatory authorities, and those other risks contained in the Company’s public filings, including in its Management Discussion and Analysis and its Annual Information Form (AIF). Factors that could cause actual results of the Company and its businesses to differ materially from those described in such forward-looking statements include, but are not limited to, a decline in the digital asset market or general economic conditions; changes in laws or approaches to regulation, the failure or delay in the adoption of digital assets and the blockchain ecosystem by institutions; changes in the volatility of crypto currency, changes in demand for Bitcoin and Ethereum, changes in the status or classification of cryptocurrency assets, cybersecurity breaches, a delay or failure in developing infrastructure for the trading businesses or achieving mandates and gaining traction; failure to grow assets under management, an adverse development with respect to an issuer or party to the transaction or failure to obtain a required regulatory approval. In connection with the forward-looking statements contained in this press release, the Company has made assumptions that no significant events occur outside of the Company’s normal course of business and that current trends in respect of digital assets continue. Readers are cautioned that the key metrics disclosed in this press release, including, without limitation,  Assets Under Management and trading volumes fluctuate and may increase and decrease from time to time and that such fluctuations are beyond the Company’s control. Forward-looking statements, past and present performance and trends are not guarantees of future performance, accordingly, you should not put undue reliance on forward-looking statements, current or past performance, or current or past trends. Information identifying assumptions, risks, and uncertainties relating to the Company are contained in its filings with the Canadian securities regulators available at www.sedar.com. The forward-looking statements in this press release are applicable only as of the date of this release or as of the date specified in the relevant forward-looking statement and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after that date or to reflect the occurrence of unanticipated events. The Company assumes no obligation to provide operational updates, except as required by law. If the Company does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements, unless required by law. Readers are cautioned that past performance is not indicative of future performance and current trends in the business and demand for digital assets may not continue and readers should not put undue reliance on past performance and current trends.  All figures are in U.S. dollars unless otherwise noted.

Press Contacts

Voyager Digital, Ltd.
Michael Legg
Chief Communications Officer
(212) 547-8807
mlegg@investvoyager.com

Voyager Public Relations Team
pr@investvoyager.com

SOURCE Voyager Digital (Canada) Ltd.

Related Links

https://www.investvoyager.com/

Release – Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

Posted on by Admin


Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

 

BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces receipt of clearance from an Australian Human Research Ethics Committee (HREC) to initiate a Phase 1 trial with its orally administered PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A.

The Phase 1 randomized, double-blind, placebo-controlled study is expected to enroll 56 healthy volunteers at a single site in Australia. The study is designed to assess the safety, tolerability and pharmacokinetics of CC-42344.

CC-42344 binds to a highly conserved PB2 site of influenza polymerase complex and exhibits a novel mechanism of action that inhibits viral replication. In preclinical testing, CC-42344 demonstrated excellent antiviral activity against influenza A strains, including avian pandemic strains and Tamiflu® and Xofluza®-resistant strains, as well as favorable pharmacokinetic and drug-resistance profiles.

“The need for a novel, broad-spectrum, oral antiviral for pandemic and seasonal influenza A is clear as current approved influenza treatments are partially effective and are prone to viral resistance,” said Sam Lee, Ph.D., Cocrystal’s President and co-interim CEO. “We discovered CC-43244 using our proprietary structure-based drug discovery platform technologies. CC-43244 is specifically designed to be effective against pandemic and seasonal influenza A strains and emerging avian influenza viruses.”

“Our decision to conduct the Phase 1 trial in Australia was due to favorable regulatory policies and a clinical trial environment that aligns with our strategy for rapid, cost-efficient and high-quality clinical development,” added James Martin, Cocrystal’s CFO and co-interim CEO. “We are delighted to begin our first clinical study with CC-42344 as a treatment for this major global health concern.”

The World Health Organization (WHO) estimate there are approximately 1 billion cases of influenza annually worldwide, resulting in 3 million to 5 million cases of severe illness and 290,000 to 650,000 deaths. The Center for Disease Control (CDC) estimates that since 2010 influenza has resulted in 9 million to 45 million illnesses in the U.S. annually, resulting in 140,000 to 810,000 hospitalizations and 12,000 to 61,000 deaths.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, hepatitis C virus and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding conducting the Phase 1 study of CC-42344 in Australia and our strategy with respect to clinical development. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from the impact of the COVID-19 pandemic on the national and global economy, on our collaboration partners, CROs, CMOs, and on our Company, including raw material and test animal shortages and other supply chain disruptions, the ability of our CROs to recruit volunteers for, and to proceed with, clinical trials, possible delays resulting from the lockdowns in Australia, potential delays related to the manufacturing of the drug for the study, the results of clinical trials, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes, and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Source: Cocrystal Pharma, Inc.